OrisDX provides a saliva-based molecular detection method to check oral cavity pre-malignancies and cancers.
OrisDX has raised $4.0M in total funding. The most recent round was Seed. The last funding was announced in June 2025.
OrisDX's investors include Polsky Center for Entrepreneurship and Innovation, Revere Partners, Illinois Department of Commerce & Economic Opportunity, The University of Chicago Medicine, SMILE Health.
OrisDX is headquartered in Chicago, United States.
OrisDX provides a saliva-based molecular detection method to check oral cavity pre-malignancies and cancers.
OrisDX is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OrisDX — Funding & Investors." VCBacked, June 10, 2025, https://www.vcbacked.co/company/orisdx. Accessed September 30, 2026.
VCBacked. (2025). OrisDX — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/orisdx
{{cite web |title=OrisDX — Funding & Investors |url=https://www.vcbacked.co/company/orisdx |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated